newsfilter
← Latest News
Business Wire·

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at